Twinkal R Upadhyay1, Nitin Kothari2, Hitesh Shah3. 1. Resident, Department of Biochemistry, H.M. Patel Centre for Medical Care and Education, Pamukh Swami Medical College and Shree Krishna Hospital , Karamsad, Gujarat, India . 2. Assistant Professor, Department of Pharmacology, Pacific Medical College and Hospital , Udaipur, Rajasthan, India . 3. Professor, Department of Biochemistry, H.M. Patel Centre for Medical Care and Education, Pamukh Swami Medical College and Shree Krishna Hospital , Karamsad, Gujarat, India .
Abstract
INTRODUCTION: Type-2 Diabetes Mellitus (T2DM) and metformin both can lower serum B12 (s.B12). Raised serum Homocysteine (s.Hcy) is considered as an early marker of B12 deficiency. AIM: The study aimed to check whether homocysteine levels are more sensitive indicator of s. B12 deficiency or not among diabetics using metformin. MATERIALS AND METHODS: Mean s.B12 and s.Hcy levels of 30 cases (diabetics on metformin <5years) were compared with 30 diabetic controls not on metformin and 31 nondiabetic controls and statistically analysed by ANOVA and post-hoc tests. RESULTS: No significant differences in either s.B12 mean or s.Hcy mean were found between cases and diabetic controls. s.B12 mean did not differ significantly but s.Hcy mean was significantly higher among nondiabetics as compared to diabetic control. s. B12 level of Nondiabetic group was in borderline category while mean s. B12 levels of cases and diabetic control groups was in normal category but nearer to the lower cut off. Mean s.Hcy values in all the groups were high. Pearson correlation showed strong association between s.B12 and s.Hcy in all the groups. Additionally equation based on linear regression was derived to calculate either of the s.B12 or s.Hcy. On Receiver Operative Characteristic (ROC) curve, area under curve value was 0.842 for the value of s.Hcy. CONCLUSION: In this study neither metformin nor T2DM could be identified as a cause for s.B12 lowering and raised s.Hcy in the scenario of low normal levels of s.B12 (<300pmol/L). If B12 deficiency recognized early using s. Hcy, consequences due to B12 deficiency can be prevented or delayed among nondiabetics as well as among diabetics and metformin users.
INTRODUCTION:Type-2 Diabetes Mellitus (T2DM) and metformin both can lower serum B12 (s.B12). Raised serum Homocysteine (s.Hcy) is considered as an early marker of B12 deficiency. AIM: The study aimed to check whether homocysteine levels are more sensitive indicator of s. B12 deficiency or not among diabetics using metformin. MATERIALS AND METHODS: Mean s.B12 and s.Hcy levels of 30 cases (diabetics on metformin <5years) were compared with 30 diabetic controls not on metformin and 31 nondiabetic controls and statistically analysed by ANOVA and post-hoc tests. RESULTS: No significant differences in either s.B12 mean or s.Hcy mean were found between cases and diabetic controls. s.B12 mean did not differ significantly but s.Hcy mean was significantly higher among nondiabetics as compared to diabetic control. s. B12 level of Nondiabetic group was in borderline category while mean s. B12 levels of cases and diabetic control groups was in normal category but nearer to the lower cut off. Mean s.Hcy values in all the groups were high. Pearson correlation showed strong association between s.B12 and s.Hcy in all the groups. Additionally equation based on linear regression was derived to calculate either of the s.B12 or s.Hcy. On Receiver Operative Characteristic (ROC) curve, area under curve value was 0.842 for the value of s.Hcy. CONCLUSION: In this study neither metformin nor T2DM could be identified as a cause for s.B12 lowering and raised s.Hcy in the scenario of low normal levels of s.B12 (<300pmol/L). If B12 deficiency recognized early using s. Hcy, consequences due to B12 deficiency can be prevented or delayed among nondiabetics as well as among diabetics and metformin users.
Authors: H Refsum; C S Yajnik; M Gadkari; J Schneede; S E Vollset; L Orning; A B Guttormsen; A Joglekar; M G Sayyad; A Ulvik; P M Ueland Journal: Am J Clin Nutr Date: 2001-08 Impact factor: 7.045
Authors: Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal Journal: JAMA Date: 2008-10-15 Impact factor: 56.272
Authors: Jolien de Jager; Adriaan Kooy; Philippe Lehert; Michiel G Wulffelé; Jan van der Kolk; Daniël Bets; Joop Verburg; Ab J M Donker; Coen D A Stehouwer Journal: BMJ Date: 2010-05-20
Authors: Matthew C Pflipsen; Robert C Oh; Aaron Saguil; Dean A Seehusen; D Seaquist; Richard Topolski Journal: J Am Board Fam Med Date: 2009 Sep-Oct Impact factor: 2.657
Authors: Lael Reinstatler; Yan Ping Qi; Rebecca S Williamson; Joshua V Garn; Godfrey P Oakley Journal: Diabetes Care Date: 2011-12-16 Impact factor: 19.112